INOVIO (INO) announced a strategic reorganization, which is expected to provide annual savings of approximately $4.3 million and includes an 11% reduction of full-time employees. The company expects to incur a one-time restructuring charge of approximately $1.1 million in the first quarter of 2023.
INOVIO stated that data readouts for its Phase 3 REVEAL2 trial for VGX-3100 and the second cohort from the Phase 1/2 trial for INO-3107 are expected to be announced in the first quarter of 2023.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News